图4. 利用B-hLAG3小鼠进行抗人LAG3抗体(Relatimab Analog)与鼠源PD-1抗体联用药效验证实验 将小鼠结肠癌细胞MC38移植到B-hLAG3纯合小鼠皮下,待肿瘤体积约150±50mm3时将动物入组至对照组和治疗组(n=10)。 结果显示:抗人LAG3抗体(Relatlimab Analog)和鼠源PD-1抗体联用对肿瘤生长具有明显的抑制作用。A...
Antitumor activity of anti-human PD-1 antibody in B-hPD-1/hPD-L1 mice.(A) Anti-human PD-L1 antibody Pembrolizumab (in house) inhibited B-hPD-L1 MC38 plus tumor growth in B-hPD-1/hPD-L1 mice. Murine colon cancer B-hPD-L1 MC38 plus cells (5×105) were subcutaneously implanted into...
(A) anti-human PD-L1 Atezolizumab (in house) combined with anti-human Triagolizumab(in house) inhibited MC38-hPD-L1 tumor growth in B-hPD-1/hPD-L1/hTIGIT mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hPD-L1/hTIGIT mice(...
Importantly, we showed that combining anti-human PD-L1 and anti-human TIGIT antibodies significantly inhibited the growth of MC38-hPD-L1 tumor cells implanted into B-hPD-1/hPD-L1/hTIGIT mice. Thus, our novel hPD-1/hPD-L1/hTIGIT TKI mice will be very useful for investigating the in vivo...
(A) Anti-human CD47/PD-L1 bispecific antibody inhibited MC38-hPD-L1-hCD47 tumor growth in B-hPD-L1/hSIRPA/hCD47 mice (female, 6-8 week-old, n=5). Mice were grouped when tumor volume reached approximately 200 mm3, at which time they were treated with different antibodies with doses ...